MX378932B - Triazoles sustituidos y métodos relacionados a estos. - Google Patents
Triazoles sustituidos y métodos relacionados a estos.Info
- Publication number
- MX378932B MX378932B MX2017009824A MX2017009824A MX378932B MX 378932 B MX378932 B MX 378932B MX 2017009824 A MX2017009824 A MX 2017009824A MX 2017009824 A MX2017009824 A MX 2017009824A MX 378932 B MX378932 B MX 378932B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- related methods
- pharmaceutically acceptable
- disclosed
- substituted triazoles
- Prior art date
Links
- 150000003852 triazoles Chemical class 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001399 1,2,3-triazolyl group Chemical class N1N=NC(=C1)* 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110415P | 2015-01-30 | 2015-01-30 | |
| US201562259314P | 2015-11-24 | 2015-11-24 | |
| PCT/US2016/015740 WO2016123533A1 (en) | 2015-01-30 | 2016-01-29 | Substituted triazoles and methods relating thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017009824A MX2017009824A (es) | 2017-11-02 |
| MX378932B true MX378932B (es) | 2025-03-10 |
Family
ID=55305123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009824A MX378932B (es) | 2015-01-30 | 2016-01-29 | Triazoles sustituidos y métodos relacionados a estos. |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9718789B2 (enExample) |
| EP (1) | EP3250563B1 (enExample) |
| JP (1) | JP6728198B2 (enExample) |
| KR (1) | KR102575601B1 (enExample) |
| CN (1) | CN107406420B (enExample) |
| AU (1) | AU2016211292B2 (enExample) |
| BR (1) | BR112017016488A2 (enExample) |
| CA (1) | CA2975474C (enExample) |
| CY (1) | CY1125082T1 (enExample) |
| DK (1) | DK3250563T3 (enExample) |
| ES (1) | ES2905878T3 (enExample) |
| HR (1) | HRP20220327T1 (enExample) |
| HU (1) | HUE058156T2 (enExample) |
| IL (1) | IL253705B (enExample) |
| LT (1) | LT3250563T (enExample) |
| MX (1) | MX378932B (enExample) |
| PL (1) | PL3250563T3 (enExample) |
| PT (1) | PT3250563T (enExample) |
| RS (1) | RS62862B1 (enExample) |
| RU (1) | RU2718049C2 (enExample) |
| SI (1) | SI3250563T1 (enExample) |
| WO (1) | WO2016123533A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TN2016000542A1 (en) | 2014-06-03 | 2018-04-04 | Idorsia Pharmaceuticals Ltd | Pyrazole compounds and their use as t-type calcium channel blockers |
| ES2693052T3 (es) | 2014-09-15 | 2018-12-07 | Idorsia Pharmaceuticals Ltd | Compuestos de triazol como bloqueantes de los canales de calcio de tipo T |
| PT3250563T (pt) | 2015-01-30 | 2022-02-09 | Neurocrine Biosciences Inc | Triazois substituídos e métodos relacionados aos mesmos |
| HRP20220463T1 (hr) | 2016-12-16 | 2022-05-27 | Idorsia Pharmaceuticals Ltd | Farmaceutska kombinacija koja sadrži blokator kalcijevih kanala t-tipa |
| WO2018141961A1 (en) | 2017-02-06 | 2018-08-09 | Idorsia Pharmaceuticals Ltd | A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes |
| KR102298546B1 (ko) * | 2018-10-18 | 2021-09-08 | 에이치케이이노엔 주식회사 | 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도 |
| CN110669017B (zh) * | 2019-10-11 | 2023-08-04 | 成都麻沸散医药科技有限公司 | 多取代三唑甲酸酯类衍生物及其用途 |
| US12570612B2 (en) | 2019-10-11 | 2026-03-10 | Chengdu Mfs Pharma. Co., Ltd. | Substituted nitrogen heterocyclic compound and anesthetic effect thereof |
| CN115974799B (zh) * | 2021-10-14 | 2024-08-13 | 成都百裕制药股份有限公司 | 氨基甲酸酯取代的醇衍生物及其在医药上的应用 |
| CN121378238B (zh) * | 2025-12-23 | 2026-03-31 | 蚌埠医科大学 | 一种芳基烷基唑类衍生物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL50699A0 (en) * | 1975-10-28 | 1976-12-31 | Ici America Inc | Triazole derivatives |
| TW513301B (en) * | 1999-03-01 | 2002-12-11 | Novartis Ag | Pharmaceutical composition for treatment of neuropathic pain and affective and attention disorders |
| HRP20050053A2 (en) * | 2002-09-19 | 2005-04-30 | Solvay Pharmaceuticals B.V. | 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
| EP1829867A1 (en) * | 2006-03-03 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Imidazole compounds having pharmaceutical activity towards the sigma receptor |
| EP1921073A1 (en) * | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,4-Triazole derivatives as sigma receptor inhibitors |
| EP1921071A1 (en) * | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,3- triazole derivatives as sigma receptor inhibitors |
| GB0722077D0 (en) * | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| US8742097B2 (en) | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| EP2752411A1 (en) * | 2013-01-07 | 2014-07-09 | Laboratorios Del Dr. Esteve, S.A. | 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders |
| PT3250563T (pt) | 2015-01-30 | 2022-02-09 | Neurocrine Biosciences Inc | Triazois substituídos e métodos relacionados aos mesmos |
-
2016
- 2016-01-29 PT PT167032507T patent/PT3250563T/pt unknown
- 2016-01-29 JP JP2017540175A patent/JP6728198B2/ja active Active
- 2016-01-29 CA CA2975474A patent/CA2975474C/en active Active
- 2016-01-29 RU RU2017130474A patent/RU2718049C2/ru active
- 2016-01-29 DK DK16703250.7T patent/DK3250563T3/da active
- 2016-01-29 PL PL16703250T patent/PL3250563T3/pl unknown
- 2016-01-29 SI SI201631489T patent/SI3250563T1/sl unknown
- 2016-01-29 LT LTEPPCT/US2016/015740T patent/LT3250563T/lt unknown
- 2016-01-29 KR KR1020177023771A patent/KR102575601B1/ko active Active
- 2016-01-29 HR HRP20220327TT patent/HRP20220327T1/hr unknown
- 2016-01-29 CN CN201680016876.2A patent/CN107406420B/zh active Active
- 2016-01-29 WO PCT/US2016/015740 patent/WO2016123533A1/en not_active Ceased
- 2016-01-29 ES ES16703250T patent/ES2905878T3/es active Active
- 2016-01-29 US US15/010,925 patent/US9718789B2/en active Active
- 2016-01-29 MX MX2017009824A patent/MX378932B/es unknown
- 2016-01-29 AU AU2016211292A patent/AU2016211292B2/en active Active
- 2016-01-29 RS RS20220093A patent/RS62862B1/sr unknown
- 2016-01-29 BR BR112017016488A patent/BR112017016488A2/pt not_active Application Discontinuation
- 2016-01-29 HU HUE16703250A patent/HUE058156T2/hu unknown
- 2016-01-29 EP EP16703250.7A patent/EP3250563B1/en active Active
-
2017
- 2017-06-22 US US15/630,225 patent/US10138214B2/en active Active
- 2017-07-27 IL IL253705A patent/IL253705B/en active IP Right Grant
-
2018
- 2018-10-29 US US16/173,025 patent/US10738017B2/en active Active
-
2020
- 2020-06-04 US US16/892,718 patent/US11021449B2/en active Active
-
2022
- 2022-03-16 CY CY20221100210T patent/CY1125082T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| CY1125082T1 (el) | Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| MX383051B (es) | Compuestos que inhiben eif4a y métodos relacionados a los mismos. | |
| TN2016000529A1 (en) | Substituted dihydroisoquinolinone compounds | |
| MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
| PH12015502443A1 (en) | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| MY202022A (en) | Pyrrolotriazine compounds as tam inhibitors | |
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| TN2015000034A1 (en) | Derivatives of azaindazole or diazaindazole type for treating pain | |
| HK1212207A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| TN2018000393A1 (en) | Pegylated carfilzomib compounds | |
| TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| MX2018001992A (es) | Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa. | |
| IN2014DN07224A (enExample) | ||
| SA518390920B1 (ar) | مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة | |
| PH12020551343A1 (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| IN2014DN07954A (enExample) | ||
| IN2014DN07220A (enExample) | ||
| MX386501B (es) | Compuestos terapeuticos y sus metodos de uso | |
| WO2012107735A3 (en) | Treatment of bipolar disorder | |
| TN2016000459A1 (en) | Cycloalkyl-linked diheterocycle derivatives. |